What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on β-Lactam/β-Lactamase Inhibitor Combinations

Clinics in Laboratory Medicine
Henrietta AbodakpiVincent H Tam

Abstract

As a class, β-lactamase inhibitors have proved successful in extending the clinical utility of β-lactam antibiotics by circumventing β-lactamase-mediated resistance. However, the rapid evolution of these β-lactamases calls for a critical reevaluation of the relationships between susceptibility, drug exposures, and bacterial response. The existing paradigm for in vitro susceptibility testing and development of β-lactam/β-lactamase inhibitor combinations may not optimally facilitate clinical use. Thus, alternative approaches for pairing these combinations and evaluating in vitro susceptibility are needed to provide better guidance to clinicians.

Citations

Nov 13, 2020·Clinical Microbiology Reviews·Dafna YahavLeonard Leibovici
Mar 26, 2021·Frontiers in Microbiology·Yanqin HuangZackery P Bulman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Related Papers

Expert Opinion on Therapeutic Patents
Karen Bush, Mark J Macielag
Mini Reviews in Medicinal Chemistry
Jiao ChenWenbing Yao
Infectious Diseases
Kenneth ChanHusam El-Mugamar
MedChemComm
Kamaleddin H M E Tehrani, Nathaniel I Martin
© 2021 Meta ULC. All rights reserved